Quantcast
Last updated on April 18, 2014 at 12:48 EDT

Latest Beta cell Stories

2010-06-15 00:36:19

Insulin-producing beta cells can proliferate in patients recently diagnosed with type 1 diabetes Researchers from the Peninsula Medical School, working in collaboration with colleagues from Glasgow Royal Infirmary and the University of Brighton, have used a unique collection of pancreas specimens taken from patients who died soon after diagnosis of type 1 diabetes to show that they respond to the ongoing process of destruction by inducing their islet cells to proliferate. The research is...

2010-06-07 20:10:59

Researchers from the La Jolla Institute and University of Virginia find protein key to insulin secretion If you think of diabetes onset like an elaborate molecular drama, then a research team led by a La Jolla Institute scientist has unmasked a previously unknown cellular player, which is critical to proper insulin secretion. "Defective insulin secretion is a hallmark of both type 1 and type 2 diabetes," said Catherine Hedrick, Ph.D., a scientist at the La Jolla Institute for Allergy &...

2010-05-25 08:04:03

Underlying all forms of diabetes is dysfunction of cells in the pancreas known as beta cells. The dysfunction is, in part, a result of inflammation mediated by soluble immune molecules known as cytokines. Greater understanding is needed of the molecular mechanisms by which beta cells respond to cytokines if protective therapeutics are to be developed. Insight into this issue has now been generated in mice by researchers, led by Raghavendra G. Mirmira, at Indiana University School of Medicine,...

2010-05-17 08:46:00

ATLANTA, May 17 /PRNewswire-USNewswire/ -- Dr. Bruce Bode announced today that he is now recruiting adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy...

2010-05-13 08:56:00

PHILADELPHIA, May 13 /PRNewswire/ -- By 2020, new cases of Type 1 diabetes in children younger than five are expected to double if current trends continue, according to a study published in The Lancet. Diabetes is an epidemic, with numbers of those suffering from diabetes and its complications increasing worldwide. The International Diabetes Foundation estimates there are 246 million adults worldwide suffering from diabetes today; by 2025, the figure is expected to reach 380 million....

2010-05-10 08:32:00

WELLINGTON, Fla., May 10 /PRNewswire-USNewswire/ -- Dr. Richard Hays announced today that he is now recruiting children with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no...

2010-05-10 09:47:44

In the first study of its type, Australian researchers have shown that healthy people with a genetic predisposition to Type 2 diabetes gain more weight overeating over the short term than their non-genetically-prone counterparts. In a 28-day study undertaken at Sydney's Garvan Institute of Medical Research, scientists set out to mimic the kind of overfeeding that typically takes place during feasting periods like Christmas. Seventeen (otherwise healthy) people with a family history of Type 2...

2010-05-05 20:18:00

SAN DIEGO, May 5 /PRNewswire/ -- ViaCyte, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today that it has received three additional U.S. Patents: On April 13, the Company was granted U.S. Patent 7,695,963, entitled "Methods for Increasing Definitive Endoderm Production". Methods described in this patent can improve the yield in manufacturing of definitive endoderm and also cells derived from it. On April 13, the Company was also granted U.S....

2010-05-05 20:13:00

SAN DIEGO, May 5 /PRNewswire/ -- Novocell, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today the Company's shareholders and Board of Directors approved a name change to ViaCyte, Inc. The name ViaCyte retains the Company's identity as a leading cell therapy company, as "-cyte" is derived from the Greek "kytos," which means cell. As the Company is moving towards the market, clear and unambiguous brand recognition is increasingly important. With...

2010-04-15 07:41:18

Mass. General, Boston University researchers run first clinical trial of system using 2 hormones An artificial pancreas system that closely mimics the body's blood sugar control mechanism was able to maintain near-normal glucose levels without causing hypoglycemia in a small group of patients. The system, combining a blood glucose monitor and insulin pump technology with software that directs administration of insulin and the blood-sugar-raising hormone glucagon, was developed at Boston...


Latest Beta cell Reference Libraries

0_0d961f30bdfa64859d9b869b063ddcd2
2010-12-03 18:12:26

Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...

More Articles (1 articles) »